Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- (-) Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- (-) Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- (-) Policy & Regulatory Barriers
- (-) Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Display Only
Showing 14 Results
NPC in Health Affairs: Payment Innovation Not Keeping Up
In a Health Affairs Blog article, NPC and MIT researchers outline how a new rule from CMS may fall short of what is needed to improve patient access to durable cell and gene therapies that target…
Walking the Walk: Taking Needed Steps to Reduce Low-Value Care
Three leading researchers detail steps to reduce low-value care in the latest edition of The American Journal of Managed Care. Their approach complements a similar effort, the Roadmap for Addressing…
NPC Weighs in on NQF’s Draft Report on Patient-Reported Outcomes
The National Pharmaceutical Council (NPC) submitted comments to the National Quality Forum (NQF) regarding the Patient-Reported Outcomes: Best Practices on Selection and Data Collection draft report…
Addressing Low-Value Care in the Time of COVID-19
The COVID-19 pandemic has had an enormous economic impact that is being felt across our communities, businesses and the overall health care system. It has placed a larger spotlight on the challenges…
Sustainable Solutions for Patients’ Sake
Blasine Penkowski, Chair of NPC's Board of Directors, proposes some guiding principles on how we can move toward a post-COVID world and build a more resilient system where patients have the care they…
NPC Statement on Racial, Social Injustices and Health Disparities
The recent deaths of George Floyd, Ahmaud Arbery and Breonna Taylor have put a spotlight on the racial and social injustices that are unfortunately pervasive in the United States. The COVID-19…
How Do We Place a Value on Indirect Treatment Benefits Like Quality of Life?
A study from NPC and RTI Health Solutions evaluated how institutional barriers prevent the inclusion of broader individual and societal benefits associated with new health care innovations from being…
NPC Weighs in on CMS Oncology Care First Model
NPC submitted comments regarding the Centers for Medicare and Medicaid Services Center for Medicare and Medicaid Innovation informal request for information on the Oncology Care First Model.
NPC and PQA Call for Research Proposals on Barriers to Medication Access
The National Pharmaceutical Council and (NPC) and the Pharmacy Quality Alliance (PQA) announced a new funding opportunity, aimed at supporting research to identify systemic approaches for lowering…
FDA’s Real-World Data and Evidence Framework Is a Good Step Forward
The U.S. Food and Drug Administration today released its framework for evaluating the potential use of real-world evidence (RWE) to help support the approval of a new indication for a pre-approved…
Real-World Data in the Current Health Care Environment
In this guest blog post, Dr. Eberechukwu Onukwugha of the University of Maryland School of Pharmacy's Department of Pharmaceutical Health Services Research explores the value of real-world data.
NPC at ISPOR 2018: Gathering and Curating Real-World Data
The use and importance of real-world evidence (RWE) in clinical decision-making has been frequently cited by Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb, so it’s not surprising…
Breaking Down Regulatory Barriers to Value Pricing for Prescription Drugs
Paying for prescription medicines based on their value to patients is increasingly seen as a promising technique to combat rising medication costs. But while other parts of the health care sector are…
How Can We Address Barriers to Accessing Needed Care?
In the latest issue of the American Journal of Pharmacy Benefits, NPC's Chief Science Officer Robert Dubois, MD, PhD, outlines some of the challenges consumers are facing with high-deductible health…